Liposomes and virosomes as delivery systems for antigens, nucleic acids and drugs

Current Opinion in Biotechnology

Volumn 15, Issue 6, 2004, Pages 518-529

  Felnerova, Diana ^a   Viret, Jean François ^a   Glück, Reinhard ^a   Moser, Christian ^a  

^a Berna Biotech AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AUTO-IMMUNITY; CHRONIC INFECTIONS; LIPOSOMES; VIROSOMES;

BIOTECHNOLOGY; DISEASES; DRUG PRODUCTS; ENCAPSULATION; IMMUNOLOGY; LIPIDS; NUCLEIC ACIDS; PROTEINS; TOXICITY; TUMORS; VACCINES;

ANTIGENS;

ALLOVECTIN; AMPHOTERICIN; AMPHOTERICIN B LIPID COMPLEX; ANNAMYCIN; ANTISENSE OLIGONUCLEOTIDE; ATRA IV; BETA 2 MICROGLOBULIN; BUDESONIDE; CLODRONIC ACID; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DAUNORUBICIN; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; EVACET; GLUCOCORTICOID; HEPATITIS A VACCINE; HLA B ANTIGEN; INFLEXAL; INFLUENZA VACCINE; INTERLEUKIN 2; LEROFON; LIPOSOME; LURTOTECAN; MITOXANTRONE; MUCIN; NUCLEIC ACID; NYSTATIN; ONCO TCS; PACLITAXEL; PLASMID DNA; PLATINUM; PLATINUM 1,2 DIAMINOCYCLOHEXANE BISNEODECANOATE; PREDNISOLONE; RETINOIC ACID; TACROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE; VIROSOME;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTHRITIS; ASTHMA; AUTOIMMUNITY; BIRD DISEASE; BLADDER CANCER; BREAST CANCER; CLINICAL TRIAL; DIABETES MELLITUS; DIPHTHERIA; DRUG DELIVERY SYSTEM; EPIDEMIC ENCEPHALITIS; FOLLICULAR LYMPHOMA; GENE DELIVERY SYSTEM; GENE THERAPY; GLIOMA; HEAD AND NECK CANCER; HEPATITIS A; HEPATITIS C; HUMAN; IMMUNE RESPONSE; IMMUNITY; INFECTION; INFLUENZA; KAPOSI SARCOMA; KIDNEY CANCER; LEUKEMIA; LUNG CANCER; MALARIA; MULTIPLE MYELOMA; MUMPS; NEUROBLASTOMA; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; RESPIRATORY TRACT DISEASE; REVIEW; SARCOMA; SKIN CANCER; STOMACH CANCER; STOMATITIS; TETANUS; UTERINE CERVIX CANCER; VACCINATION; VISCERAL LEISHMANIASIS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS; DRUG DELIVERY SYSTEMS; GENE THERAPY; HUMANS; LIPOSOMES; NUCLEIC ACIDS; PHARMACEUTICAL PREPARATIONS; VACCINES; VIROSOMES;

EID: 9244234954     PISSN: 09581669     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.copbio.2004.10.005     Document Type: Review

References (88)

1. A.D. Bangham, M.M. Standish, and N. Miller Cation permeability of phospholipid model membranes: effect of narcotics Nature 208 1965 1295 1297
2. A.G. Allison, and G. Gregoriadis Liposomes as immunological adjuvants Nature 252 1974 252
3. R. Gluck, R. Mischler, S. Brantschen, M. Just, B. Althaus, and S.J. Cryz Jr. Immunopotentiating reconstituted influenza virus virosome vaccine delivery system for immunization against hepatitis A J Clin Invest 90 1992 2491 2495
4. C. Moser, I.C. Metcalfe, and J.-F. Viret Virosomal adjuvanted antigen delivery systems Expert Rev Vaccines 2 2003 189 196 This is an actual update on the influenza virosomes including the newest knowledge on the structural and immunological properties of the virosomes. Additionally, a description of clinically tested products is included.
5. G.F. Kersten, and D.J. Crommelin Liposomes and ISCOMs Vaccine 21 2003 915 920
6. A. Gabizon, D. Goren, R. Cohen, and Y. Barenholz Development of liposomal anthracyclines: from basics to clinical applications J Control Release 53 1998 275 279
7. D.C. Drummond, M. Zignani, and J. Leroux Current status of pH-sensitive liposomes in drug delivery Prog Lipid Res 39 2000 409 460
8. G. Zuber, E. Dauty, M. Nothisen, P. Belguise, and J.P. Behr Towards synthetic viruses Adv Drug Deliv Rev 52 2001 245 253
9. Y. Shoji, and H. Nakashima Current status of delivery systems to improve target efficacy of oligonucleotides Curr Pharm Des 10 2004 785 796
10. N.C. Templeton Cationic liposomes as in vivo delivery vehicles Curr Med Chem 10 2003 1279 1287
11. C.P. Tilcock Lipid polymorphism Chem Phys Lipids 40 1986 109 125
12. J.H. Senior Fate and behavior of liposomes in vivo: a review of controlling factors Crit Rev Ther Drug Carrier Syst 3 1987 123 193
13. Y.S. Park, K. Maruyama, and L. Huang Some negatively charged phospholipid derivatives prolong the liposome circulation in vivo Biochim Biophys Acta 1108 1992 257 260
14. M.C. Woodle, K.K. Matthay, M.S. Newman, J.E. Hidayat, L.R. Collins, C. Redemann, F.J. Martin, and D. Papahadjopoulos Versatility in lipid compositions showing prolonged circulation with sterically stabilized liposomes Biochim Biophys Acta 1105 1992 193 200
15. I. Tranchant, B. Thompson, C. Nicolazzi, N. Mignet, and D. Scherman Physicochemical optimisation of plasmid delivery by cationic lipids J Gene Med Suppl 1 2004 S24 S35
16. X. Guo, and F.C. Szoka Jr. Chemical approaches to triggerable lipid vesicles for drug and gene delivery Acc Chem Res 36 2003 335 341 This is an excellent review on the physicochemistry that can be applied to exploit pH and redox potential, aiming at the release of vesicle contents in an appropriate biological location.
17. H. Ellens, J. Bentz, and F.C. Szoka pH-induced destabilization of phosphatidylethanolamine-containing liposomes: role of bilayer contact Biochemistry 23 1984 1532 1538
18. X. Guo, and F.C. Szoka Jr. Steric stabilization of fusogenic liposomes by a low-pH sensitive PEG-diortho ester-lipid conjugate Bioconjug Chem 12 2001 291 300
19. J.X. Zhang, S. Zalipsky, N. Mullah, M. Pechar, and T.M. Allen Pharmaco attributes of dioleoylphosphatidylethanolamine/cholesterylhemisuccinate liposomes containing different types of cleavable lipopolymers Pharmacol Res 49 2004 185 198
20. L.H. Lindner, M.E. Eichhorn, H. Eibl, N. Teichert, M. Schmitt-Sody, R.D. Issels, and M. Dellian Novel temperature-sensitive liposomes with prolonged circulation time Clin Cancer Res 10 2004 2168 2178
21. D. Needham, and M.W. Dewhirst The development and testing of a new temperature-sensitive drug delivery system for the treatment of solid tumors Adv Drug Deliv Rev 53 2001 285 305
22. E. Mastrobattista, D.J. Crommelin, J. Wilschut, and G. Storm Targeted liposomes for delivery of protein-based drugs into the cytoplasm of tumor cells J Liposome Res 12 2002 57 65
23. L. Bungener, A. Huckriede, J. Wilschut, and T. Daemen Delivery of protein antigens to the immune system by fusion-active virosomes: a comparison with liposomes and ISCOMs Biosci Rep 22 2002 323 338 Fusion activity of HA in virosomes enables the escape of the antigens from processing in the MHC II processing pathway. Liposomes and ISCOMS (immune-stimulating complexes based on saponin adjuvant QuilA) do not possess this feature.
24. J.K. Kim, S.H. Choi, C.O. Kim, J.S. Park, W.S. Ahn, and C.K. Kim Enhancement of polyethylene glycol (PEG)-modified cationic liposome-mediated gene deliveries: effects on serum stability and transfection efficiency J Pharm Pharmacol 55 2003 453 460
25. C. Allen, N. Dos Santos, R. Gallagher, G.N. Chiu, Y. Shu, W.M. Li, S.A. Johnstone, A.S. Janoff, L.D. Mayer, M.S. Webb, and M.B. Bally Controlling the physical behavior and biological performance of liposome formulations through use of surface grafted poly(ethylene glycol) Biosci Rep 22 2002 225 250
26. V.D. Awasthi, D. Garcia, R. Klipper, B.A. Goins, and W.T. Phillips Neutral and anionic liposome-encapsulated hemoglobin: effect of postinserted poly(ethylene glycol) -distearoylphosphatidylethanolamine on distribution and circulation kinetics J Pharmacol Exp Ther 309 2004 241 248
27. C. Brignole, D. Marimpietri, C. Gambini, T.M. Allen, M. Ponzoni, and F. Pastorino Development of Fab' fragments of anti-GD(2) immunoliposomes entrapping doxorubicin for experimental therapy of human neuroblastoma Cancer Lett 197 2003 199 204
28. P. Sapra, and T.M. Allen Ligand-targeted liposomal anticancer drugs Prog Lipid Res 42 2003 439 462 Considers important aspects with regard to the selection of appropriate target molecules, target ligands, biocompatibility of the drugs with the liposomal system and possible techniques for the coupling of ligands to liposomes.
29. T.S. Levchenko, R. Rammohan, N. Volodina, and V.P. Torchilin Tat peptide-mediated intracellular delivery of liposomes Methods Enzymol 372 2003 339 349
30. G. Elliott, and P. O'Hare Intercellular trafficking and protein delivery by a herpesvirus structural protein Cell 88 1997 223 233
31. V.P. Torchilin, and T.S. Levchenko TAT-liposomes: a novel intracellular drug carrier Curr Protein Pept Sci 4 2003 133 140
32. J.P. Colletier, B. Chaize, M. Winterhalter, and D. Fournier Protein encapsulation in liposomes: efficiency depends on interactions between protein and phospholipid bilayer BMC Biotechnol 2 2002 9
33. S.A. Abraham, C. McKenzie, D. Masin, R. Ng, T.O. Harasym, L.D. Mayer, and M.B. Bally In vitro and in vivo characterization of doxorubicin and vincristine coencapsulated within liposomes through use of transition metal ion complexation and pH gradient loading Clin Cancer Res 10 2004 728 738
34. P.J. Stevens, and R.J. Lee Formulation kit for liposomal doxorubicin composed of lyophilized liposomes Anticancer Res 23 2003 439 442
35. N. Duzgunes Preparation and quantitation of small unilamellar liposomes and large unilamellar reverse-phase evaporation liposomes Methods Enzymol 367 2003 23 27
36. S. Pautot, B.J. Frisken, and D.A. Weitz Engineering asymmetric vesicles Proc Natl Acad Sci USA 100 2003 10718 10721
37. J.D. Almeida, D.C. Edwards, C.M. Brand, and T.D. Heath Formation of virosomes from influenza subunits and liposomes Lancet 2 1975 899 901
38. R. Zurbriggen Immunostimulating reconstituted influenza virosomes Vaccine 21 2003 921 924
39. J. Shoji, Y. Tanihara, T. Uchiyama, and A. Kawai Preparation of virosomes coated with the vesicular stomatitis virus glycoprotein as efficient gene transfer vehicles for animal cells Microbiol Immunol 48 2004 163 174
40. D.R. Kapczynski, and T.M. Tumpey Development of a virosome vaccine for Newcastle disease virus Avian Dis 47 2003 578 587
41. H.S. Kim, and Y.S. Park Effect of lipid compositions on gene transfer into 293 cells using Sendai F/HN-virosomes J Biochem Mol Biol 35 2002 459 464
42. R. Gluck, and I.C. Metcalfe Novel approaches in the development of immunopotentiating reconstituted influenza virosomes as efficient antigen carrier systems Vaccine 21 2003 611 615
43. E. Waelti, N. Wegmann, R. Schwaninger, A. Wetterwald, C. Wingenfeld, B. Rothen-Rutishauser, and C.D. Gimmi Targeting her-2/neu with antirat Neu virosomes for cancer therapy Cancer Res 62 2002 437 444
44. A. Huckriede, L. Bungener, W. ter Veer, M. Holtrop, T. Daemen, A.M. Palache, and J. Wilschut Influenza virosomes: combining optimal presentation of hemagglutinin with immunopotentiating activity Vaccine 21 2003 925 931
45. M.F. Bachmann, H. Hengartner, and R.M. Zinkernagel T helper cell-independent neutralizing B cell response against vesicular stomatitis virus: role of antigen patterns in B cell induction? Eur J Immunol 25 1995 3445 3451
46. + T cell activation Vaccine 22 2004 714 723
47. R. Mischler, and I.C. Metcalfe Inflexal V a trivalent virosome subunit influenza vaccine: production Vaccine 20 Suppl 5 2002 B17 B23
48. R. Zurbriggen, I. Novak-Hofer, A. Seelig, and R. Gluck IRIV-adjuvanted hepatitis A vaccine: in vivo absorption and biophysical characterization Prog Lipid Res 39 2000 3 18
49. R. Gluck, R. Mischler, S. Brantschen, M. Just, B. Althaus, and S.J. Cryz Jr. Immunopotentiating reconstituted influenza virus virosome vaccine delivery system for immunization against hepatitis A J Clin Invest 90 1992 2491 2495
50. M.S. Mueller, A. Renard, F. Boato, D. Vogel, M. Naegeli, R. Zurbriggen, J.A. Robinson, and G. Pluschke Induction of parasite growth-inhibitory antibodies by a virosomal formulation of a peptidomimetic of loop I from domain III of Plasmodium falciparum apical membrane antigen 1 Infect Immun 71 2003 4749 4758
51. I.P. Hunziker, B. Grabscheid, R. Zurbriggen, R. Gluck, W.J. Pichler, and A. Cerny In vitro studies of core peptide-bearing immunopotentiating reconstituted influenza virosomes as a non-live prototype vaccine against hepatitis C virus Int Immunol 14 2002 615 626
52. M.G. Cusi, R. Zurbriggen, P. Correale, M. Valassina, C. Terrosi, L. Pergola, P.E. Valensin, and R. Gluck Influenza virosomes are an efficient delivery system for respiratory syncytial virus-F antigen inducing humoral and cell-mediated immunity Vaccine 20 2002 3436 3442
53. P. Correale, M.G. Cusi, M. Sabatino, L. Micheli, D. Pozzessere, C. Nencini, P.E. Valensin, R. Petrioli, G. Giorgi, and R. Zurbriggen Tumour-associated antigen (TAA)-specific cytotoxic T cell (CTL) response in vitro and in a mouse model, induced by TAA-plasmids delivered by influenza virosomes Eur J Cancer 37 2001 2097 2103
54. E.R. Waelti, and R. Gluck Delivery to cancer cells of antisense L-myc oligonucleotides incorporated in fusogenic, cationic-lipid-reconstituted influenza-virus envelopes (cationic virosomes) Int J Cancer 77 1998 728 733
55. M.G. Cusi, S. Fischer, R. Sedlmeier, M. Valassina, P.E. Valensin, M. Donati, and W.J. Neubert Localization of a new neutralizing epitope on the mumps virus hemagglutinin-neuraminidase protein Virus Res 74 2001 133 137
56. A. Scardino, P. Correale, H. Firat, M. Pellegrini, K. Kosmatopoulos, P. Opolon, P. Alves, R. Zurbriggen, R. Gluck, and F.A. Lemonnier In vivo study of the GC90/IRIV vaccine for immune response and autoimmunity into a novel humanised transgenic mouse Br J Cancer 89 2003 199 205
57. S. Sofou, J.L. Thomas, H.Y. Lin, M.R. McDevitt, D.A. Scheinberg, and G. Sgouros Engineered liposomes for potential α-particle therapy of metastatic cancer J Nucl Med 45 2004 253 260
58. N. Oku, T. Asai, K. Watanabe, K. Kuromi, K. Ogino, and T. Taki Anti-neovascular therapy by use of liposomes targeted to angiogenic vessels J Liposome Res 13 2003 25 27
59. L.A. Lopez-Barcons, D. Polo, F. Reig, and A. Fabra Pentapeptide YIGSR-mediated HT-1080 fibrosarcoma cells targeting of adriamycin encapsulated in sterically stabilized liposomes J Biomed Mater Res 69A 2004 155 163
60. S. Hosokawa, T. Tagawa, H. Niki, Y. Hirakawa, K. Nohga, and K. Nagaike Efficacy of immunoliposomes on cancer models in a cell-surface-antigen-density- dependent manner Br J Cancer 89 2003 1545 1551
61. P. Sapra, and T.M. Allen Improved outcome when B-cell lymphoma is treated with combinations of immunoliposomal anticancer drugs targeted to both the CD19 and CD20 epitopes Clin Cancer Res 10 2004 2530 2537
62. J. Schmidt, J.M. Metselaar, and R. Gold Intravenous liposomal prednisolone downregulates in situ TNF-α production by T-cells in experimental autoimmune encephalomyelitis J Histochem Cytochem 51 2003 1241 1244
63. M.B. Jordan, N. van Rooijen, S. Izui, J. Kappler, and P. Marrack Liposomal clodronate as a novel agent for treating autoimmune hemolytic anemia in a mouse model Blood 101 2003 594 601
64. C.G. Park, N.W. Thiex, K.M. Lee, G.L. Szot, J.A. Bluestone, and K.D. Lee Targeting and blocking B7 costimulatory molecules on antigen-presenting cells using CTLA4Ig-conjugated liposomes: in vitro characterization and in vivo factors affecting biodistribution Pharm Res 20 2003 1239 1248
65. J.M. Metselaar, M.H. Wauben, J.P. Wagenaar-Hilbers, O.C. Boerman, and G. Storm Complete remission of experimental arthritis by joint targeting of glucocorticoids with long-circulating liposomes Arthritis Rheum 48 2003 2059 2066
66. K.S. Konduri, S. Nandedkar, N. Duzgunes, V. Suzara, J. Artwohl, R. Bunte, and P.R. Gangadharam Efficacy of liposomal budesonide in experimental asthma J Allergy Clin Immunol 111 2003 321 327
67. M. Erdogan, J.R. Wright Jr., and V.C. McAlister Liposomal tacrolimus lotion as a novel topical agent for treatment of immune-mediated skin disorders: experimental studies in a murine model Br J Dermatol 146 2002 964 967
68. E. Kanaoka, K. Takahashi, T. Yoshikawa, H. Jizomoto, Y. Nishihara, and K. Hirano Continuous release of interleukin-2 from liposomal IL-2 (mixture of interleukin-2 and liposomes) after subcutaneous administration to mice Drug Dev Ind Pharm 29 2003 1149 1153
69. R. Schiffelers, G. Storm, and I. Bakker-Woudenberg Liposome-encapsulated aminoglycosides in pre-clinical and clinical studies J Antimicrob Chemother 48 2001 333 344
70. Y. Gutierrez-Puente, A.M. Tari, R.J. Ford, R. Tamez-Guerra, R. Mercado-Hernandez, M. Santoyo-Stephano, and G. Lopez-Berestein Cellular pharmacology of P-ethoxy antisense oligonucleotides targeted to Bcl-2 in a follicular lymphoma cell line Leuk Lymphoma 44 2003 1979 1985
71. S. Noguchi, N. Hirashima, T. Furuno, and M. Nakanishi Remarkable induction of apoptosis in cancer cells by a novel cationic liposome complexed with a bcl-2 antisense oligonucleotide J Control Release 88 2003 313 320
72. A. Ito, F. Matsuoka, H. Honda, and T. Kobayashi Antitumor effects of combined therapy of recombinant heat shock protein 70 and hyperthermia using magnetic nanoparticles in an experimental subcutaneous murine melanoma Cancer Immunol Immunother 53 2004 26 32
73. D.N. Waterhouse, W.H. Dragowska, K.A. Gelmon, L.D. Mayer, and M.B. Bally Pharmacodynamic behavior of liposomal antisense oligonucleotides targeting Her-2/neu and vascular endothelial growth factor in an ascitic MDA435/LCC6 human breast cancer model Cancer Biol Ther 3 2004 197 204
74. C. Brignole, G. Pagnan, D. Marimpietri, E. Cosimo, T.M. Allen, M. Ponzoni, and F. Pastorino Targeted delivery system for antisense oligonucleotides: a novel experimental strategy for neuroblastoma treatment Cancer Lett 197 2003 231 235
75. J. Yoshida, M. Mizuno, M. Fujii, Y. Kajita, N. Nakahara, M. Hatano, R. Saito, M. Nobayashi, and T. Wakabayashi Human gene therapy for malignant gliomas (glioblastoma multiforme and anaplastic astrocytoma) by in vivo transduction with human interferon β gene using cationic liposomes Hum Gene Ther 15 2004 77 86
76. J. Kita, E. Kobayashi, A. Hishinuma, and Y. Kaneda Genetic modification of cold-preserved renal grafts using HSP70 or bcl-2 HVJ-liposome method Transpl Immunol 11 2003 7 14
77. M. Ulanova, L. Puttagunta, M.K. Kim, A.D. Schreiber, and A.D. Befus Antisense oligonucleotides to Syk kinase: a novel therapeutic approach for respiratory disorders Curr Opin Investig Drugs 4 2003 552 555
78. Y. Tanaka, M. Kasai, M. Taneichi, S. Naito, H. Kato, M. Mori, M. Nishida, N. Maekawa, H. Yamamura, K. Komuro, and T. Uchida Liposomes with differential lipid components exert differential adjuvanticity in antigen-liposome conjugates via differential recognition by macrophages Bioconjug Chem 15 2004 35 40
79. + T-cell response using CpG oligodeoxynucleotides and HER-2/neu-derived peptide co-encapsulated in liposomes Vaccine 21 2003 3319 3329
80. Y. Zhang, F. Schlachetzki, J.Y. Li, R.J. Boado, and W.M. Pardridge Organ-specific gene expression in the rhesus monkey eye following intravenous non-viral gene transfer Mol Vis 9 2003 465 472
81. S.C. Wu, C.H. Yu, C.W. Lin, and I.M. Chu The domain III fragment of Japanese encephalitis virus envelope protein: mouse immunogenicity and liposome adjuvanticity Vaccine 21 19-20 2003 2516 2522
82. C.P. Locher, S.A. Witt, B.M. Ashlock, and J.A. Levy Evaluation of genetic immunization adjuvants to improve the effectiveness of a human immunodeficiency virus type 2 (HIV-2) envelope DNA vaccine DNA Cell Biol 23 2004 107 110
83. M.J. Alvarez, S. Echechipia, B. Garcia, A.I. Tabar, S. Martin, P. Rico, and J.M. Olaguibel Liposome-entrapped D. pteronyssinus vaccination in mild asthma patients: effect of 1-year double-blind, placebo-controlled trial on inflammation, bronchial hyperresponsiveness and immediate and late bronchial responses to the allergen Clin Exp Allergy 32 2002 1574 1582
84. T. Mazumdar, K. Anam, and N. Ali A mixed Th1/Th2 response elicited by a liposomal formulation of Leishmania vaccine instructs Th1 responses and resistance to Leishmania donovani in susceptible BALB/c mice Vaccine 22 2004 1162 1171
85. R. Zurbriggen, and R. Gluck Immunogenicity of IRIV - versus alum-adjuvanted diphtheria and tetanus toxoid vaccines in influenza primed mice Vaccine 17 1999 1301 1305
86. E. Mastrobattista, P. Schoen, J. Wilschut, D.J. Crommelin, and G. Storm Targeting influenza virosomes to ovarian carcinoma cells FEBS Lett 509 2001 71 76
87. J.E. Cho, H.S. Kim, W.S. Ahn, and Y.S. Park Enhanced cytotoxicity of doxorubicin encapsulated in liposomes with reconstituted Sendai F-proteins J Microencapsul 18 2001 421 431
88. B. Cornet, E. Decroly, D. Thines-Sempoux, J.M. Ruysschaert, and M. Vandenbranden Properties of HIV membrane reconstituted from its recombinant gp160 envelope glycoprotein AIDS Res Hum Retroviruses 8 1992 1823 1831